GlassScriptPhysician profile
Colombia E Ptacek
NPI 1083102933
$2,864.05
in general payments reported to CMS, 2019-2025
27 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $234 · 2023: $728 · 2024: $1,077 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.15 |
| Education | $191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $403.37 | 2023-2025 | Dupixent |
| Abbvie INC. | $400.79 | 2021-2025 | |
| Janssen Biotech, INC. | $361.27 | 2024-2025 | Stelara, Tremfya |
| Genzyme Corporation | $291.92 | 2023-2024 | |
| Ardelyx, INC. | $154.37 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.94 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $139.38 | 2022-2024 | Eohilia |
| Astrazeneca Pharmaceuticals LP | $123.56 | 2021 | |
| Gilead Sciences, INC. | $114.42 | 2025 | Livdelzi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.01 | 2021-2022 | |
| Pfizer INC. | $73.08 | 2023-2024 | |
| Abbott Laboratories | $64.79 | 2021 | |
| Qol Medical, LLC | $56.59 | 2023-2024 | Sucraid, Sucraid |
| Boston Scientific Corporation | $52.99 | 2021 | |
| Medtronic, INC. | $46.27 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $44.52 | 2021 | |
| Celgene Corporation | $42.07 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $38.37 | 2024 | Dificid |
| Aimmune Therapeutics, INC. | $33.72 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.08 | 2023 | Stiolto Respimat, Jardiance |
| Phathom Pharmaceuticals, INC. | $27.87 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $25.78 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $23.49 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $22.75 | 2023 | |
| Celltrion USA INC. | $18.98 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $15.46 | 2023 | Rebyota |
| Novartis Pharmaceuticals Corporation | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colombia Ptacek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.